ArticleTranslational lung cancer research2019
Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis.
Article in Translational lung cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Anlotinib Plus Immune Checkpoint Inhibitors versus Chemotherapy in Elderly Patients with Extensive-Stage Small-Cell Lung Cancer: A Real World, Exploratory Study.Drug design, development and therapy · 2026Article
- Ultrasound-triggered doxorubicin targeted delivery for liver cancer treatment: Reduced toxicity and improved efficacy.PloS one · 2026Article
- Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study.Journal of clinical medicine · 2025Article
- The combination of chemotherapy and immune checkpoint inhibitors in recurrent extensive-stage small cell lung cancer: a case report.Journal of cardiothoracic surgery · 2025Article
- Lignin-Based Nanocarrier for Simultaneous Delivery ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Combination of anlotinib and second-line chemotherapy as surrogate to reduce immunosuppression in patients with advanced non-small cell lung cancer.Pakistan journal of medical sciences · 2024Article
- Enhancing Curcumin's therapeutic potential in cancer treatment through ultrasound mediated liposomal delivery.Scientific reports · 2024Article
- Drug-Induced Conformational Dynamics of P-Glycoprotein Underlies the Transport of Camptothecin Analogs.International journal of molecular sciences · 2023Article
- Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer.Frontiers in pharmacology · 2022Article
- Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.Clinical Medicine Insights. Oncology · 2022Article
- Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review.Journal of thoracic disease · 2021Review
- Antitumor activities of Aspiletrein A, a steroidal saponin from Aspidistra letreae, on non-small cell lung cancer cells.BMC complementary medicine and therapies · 2021Article
- Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined.Translational lung cancer research · 2020Article
- Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis.Technology in cancer research & treatmentArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe main aim of this study was to evaluate the efficiency of second-line chemotherapy irinotecan (CPT-11), topotecan (TPT), paclitaxel (PTX) and docetaxel (DTX) in small cell lung cancer (SCLC) patients who have failure to the first-line standard treatment. The secondary aim was to evaluate the independent prognostic factors of patients who received a second line treatment.
methodsRetrospective analysis of 116 patients who received second-line chemotherapy. Patients were divided into 4 groups according to the therapy they were treated with, which were CPT-11, TPT, PTX and DTX. Progress free survival (PFS), overall survival (OS), objective response rate (ORR) and disease control rate (DCR) were evaluated for each group. Patients' data of clinical character and blood index were collected, and the prognostic factors were assessed both at univariate and multivariate levels.
resultsPatients treated with CPT-11 achieved the best median PFS and OS of 91 and 595 days, while the median PFS of TPT, PTX and DTX were 74.5, 81 and 50 days respectively. The median OS of them were 154, 168.5 and 184 days respectively. The survival curves of OS were significantly different (P=0.0069). The reaction to second-line therapy is positively correlate to the reaction to first-line therapy (P=0.012). In the multivariate analysis, treatment free interval (TFI) <90 days, lactate dehydrogenase (LDH) ≥225 U/L, neutrophil-to-lymphocyte ratio (NLR) ≥3.5 were identified as independent risk factors for poor prognosis in second-line SCLC patients.
conclusionsSecond-line chemotherapy with TPT in SCLC patients may provide better overall survival benefits. TFI <90 days, LDH ≥225 U/L and NLR ≥3.5 are independent risk factors for second-line SCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.